[HTML][HTML] Acute respiratory distress syndrome

MA Matthay, RL Zemans, GA Zimmerman… - Nature reviews Disease …, 2019 - nature.com
The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in
critically ill patients and is defined by the acute onset of noncardiogenic pulmonary oedema …

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

DE Leisman, L Ronner, R Pinotti, MD Taylor… - The Lancet …, 2020 - thelancet.com
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

E Fan, JR Beitler, L Brochard, CS Calfee… - The Lancet …, 2020 - thelancet.com
The COVID-19 pandemic has seen a surge of patients with acute respiratory distress
syndrome (ARDS) in intensive care units across the globe. As experience of managing …

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

CS Calfee, K Delucchi, PE Parsons… - The Lancet …, 2014 - thelancet.com
Background Subphenotypes have been identified within heterogeneous diseases such as
asthma and breast cancer, with important therapeutic implications. We assessed whether …

A living WHO guideline on drugs for covid-19

A Agarwal, B Rochwerg, F Lamontagne… - 2022 - scholar.sun.ac.za
This living guideline by Arnav Agarwal and colleagues (BMJ 2020; 370: m3379, doi:
10.1136/bmj. m3379) was last updated on 22 April 2022, but the infographic contained two …

Is a “cytokine storm” relevant to COVID-19?

P Sinha, MA Matthay, CS Calfee - JAMA internal medicine, 2020 - jamanetwork.com
In its most severe form, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

JG Wilson, KD Liu, H Zhuo, L Caballero… - The Lancet …, 2015 - thelancet.com
Background No effective pharmacotherapy for acute respiratory distress syndrome (ARDS)
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …

Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy

KR Famous, K Delucchi, LB Ware… - American journal of …, 2017 - atsjournals.org
Rationale: We previously identified two acute respiratory distress syndrome (ARDS)
subphenotypes in two separate randomized controlled trials with differential response to …

[HTML][HTML] Redefining critical illness

DM Maslove, B Tang, M Shankar-Hari, PR Lawler… - Nature medicine, 2022 - nature.com
Research and practice in critical care medicine have long been defined by syndromes,
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …

A living WHO guideline on drugs for covid-19

F Lamontagne, A Agarwal, B Rochwerg… - bmj, 2020 - bmj.com
Updates This is the thirteenth version (twelfth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …